AOD-9604 dosage: what's used, and why the number is borrowed

AOD-9604 is a stabilized fragment of human growth hormone — the C-terminal 177–191 region with an added N-terminal tyrosine — developed by Metabolic Pharmaceuticals as a fat-loss drug that kept the lipolytic part of GH while dropping the part that raises IGF-1 and blood sugar. That is an elegant idea, and it is the reason people still ask “what’s the dose.” The honest answer is awkward: there isn’t one in any meaningful sense, because the program that would have produced a validated dose was discontinued for lack of efficacy. For the full account of what the molecule did and didn’t do in trials, read the AOD-9604 evidence monograph first — this page is narrowly about where the circulating dose numbers come from and why they don’t carry the weight people assume.

Why a “dose” for AOD-9604 is a borrowed number

Most peptide-dosing confusion comes from a gap between pharmacology and proof. With AOD-9604 the gap is wider than usual, because the proof actively went the wrong way. Metabolic Pharmaceuticals carried the compound through human testing and into a multi-week Phase 2 obesity program; the pivotal placebo-controlled study run over roughly twelve weeks did not show a significant weight-loss advantage over placebo, and the obesity development effort was wound down afterward. So when a clinic page or a forum quotes “the dose used in trials,” it is quoting a number from a program that concluded the drug didn’t work. The figure is real in the sense that it was administered to people; it is hollow in the sense that it was never shown to produce the result it is now sold to deliver.

What doses the human work actually used

The compound grew out of clearly documented animal and mechanistic work: a synthetic lipolytic domain of human GH that increased fat metabolism in cell and rodent models without the broader growth-hormone signature.^[1][2][3] When it moved into people, the doses explored sat in the low- to mid-microgram-per-day range delivered by subcutaneous injection — the lineage of the ~300 mcg figure that circulates today. Reviews of the obesity-drug pipeline from that era list AOD-9604 among the GH-fragment candidates in clinical development, which is exactly where it stalled.^[4]The key point about those numbers is not their size but their status: they were exploratory doses in a program that did not succeed, not a regimen any regulator endorsed.

The typical online protocol — and where the number comes from

The protocol passed around in compounding-clinic and gray-market contexts is fairly uniform: AOD-9604 reconstituted from lyophilized powder and injected subcutaneously, commonly around 300 micrograms a day, sometimes timed to a fasted state on the theory that food blunts a fat-burning response. That number didn’t emerge from a dose-finding trial in living patients that established an effective amount — it is lifted from the discontinued clinical program and then hardened through repetition. Calling it “the trial dose” is technically defensible and practically misleading, because it attaches the authority of a clinical study to a figure the same studies could not connect to weight loss. The fasted-timing and daily-cadence conventions are likewise inherited habit, not validated instruction.

Reconstitution mechanics

The arithmetic of turning a vial of powder into a microgram dose is the one part of this that is genuinely deterministic — it’s just dilution. How much bacteriostatic water you add sets the concentration, and the concentration plus the dose sets how many units to draw on a U-100 insulin syringe. If you want to see exactly how a given vial size and fill volume translate into per-injection units, our peptide reconstitution calculator does the math. Worth stating plainly: the calculator computes a concentration accurately, but it cannot make a borrowed dose into a proven one. Precise reconstitution of an unvalidated regimen is still an unvalidated regimen.

Still an unregulated research peptide of unverified purity

Because AOD-9604 was never approved, nothing about the supply chain is controlled. Vials sold as “research” material carry no manufacturer guarantee of dose, purity, or even that the contents are the peptide claimed. Analytical work on AOD-9604 exists largely in the anti-doping literature — methods built to detect the compound and its metabolites in athletes — which is a telling signal of where it actually lives now: a banned-substance and gray-market molecule, not a pharmacy product.^[5] That regulatory vacuum compounds the core problem. Even if you accepted the borrowed dose, you couldn’t be confident the vial contains it.

The one reassuring fact: tolerability

There is a genuinely positive thread, and it’s worth stating clearly rather than burying. Across its development, AOD-9604 was consistently well tolerated. Its whole design rationale was to keep GH’s fat-metabolizing action while shedding the systemic growth-hormone effects, and the mechanistic and review literature is consistent with that: it did not behave like growth hormone on IGF-1 or glucose handling at the amounts studied.^[3][4] That is the rare case where the safety story is the strong part and the efficacy story is the weak part — the opposite of many peptides. A favorable tolerability profile, though, is not a reason to use a drug that didn’t work; it just means the cost of its failure was measured mostly in disappointment rather than harm.

The honest bottom line

The AOD-9604 dose people circulate — roughly 300 mcg a day, subcutaneous — is a number with a clinical-sounding pedigree and no clinical payoff behind it. It traces to a development program that was discontinued precisely because the molecule failed to outperform placebo on weight loss, so refining the dose is refining the input to an effect the evidence couldn’t find. The compound’s clean tolerability is real and to its credit; its efficacy is not. If you’re weighing AOD-9604, the useful next steps are the evidence monograph for what the trials actually showed, the related hGH fragment 176–191 evidence for the broader GH-fragment story, and a licensed clinician — not a microgram figure copied from a protocol that history already retired.